Story perspectives

Breakthrough Studies Transform Ovarian, Melanoma Cancer Testing

10/25/2025

50 11

Summary

Story summary

The Princess Margaret Cancer Centre study shows multigene sequencing detects pathogenic variants in epithelial ovarian cancer with a false-negative rate under 1%.
Among 106 tumor samples, 94.3% had detectable variants, with 28 clinically significant variants.
The findings support a tumor-first genetic testing model to streamline counseling and therapy eligibility.
A Moffitt Cancer Center study shows a gene expression test can stratify melanoma risk for lymph node metastasis, reducing unnecessary surgeries.

1 of 1

Story summary

The Princess Margaret Cancer Centre study shows multigene sequencing detects pathogenic variants in epithelial ovarian cancer with a false-negative rate under 1%.
Among 106 tumor samples, 94.3% had detectable variants, with 28 clinically significant variants.
The findings support a tumor-first genetic testing model to streamline counseling and therapy eligibility.
A Moffitt Cancer Center study shows a gene expression test can stratify melanoma risk for lymph node metastasis, reducing unnecessary surgeries.